XERS Oct 2024 2.500 call
| Previous close | 0.3500 |
| Open | 0.3500 |
| Bid | 0.1500 |
| Ask | 0.5000 |
| Strike | 2.50 |
| Expiry date | 2024-10-18 |
| Day's range | 0.3500 - 0.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 167 |
Simply Wall St.Xeris Biopharma Holdings, Inc.'s (NASDAQ:XERS) Shift From Loss To Profit
We feel now is a pretty good time to analyse Xeris Biopharma Holdings, Inc.'s ( NASDAQ:XERS ) business as it appears...
Business WireXeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
CHICAGO, June 03, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced it presented a post-hoc analysis from its previously published SONICS study on the effects of levoketoconazole (Recorlev®) in adults with Cushing’s syndrome at ENDO 2024 in Boston, June 1-4, 2024.
Business WireXeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
CHICAGO, May 30, 2024--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced topline results from its recently completed Phase 2 multi-center, open label, study of XP-8121 for the treatment of adults with hypothyroidism. XP-8121 employs the Company’s XeriSol™ formulation technology to enable a novel once-weekly SC injection
